Obeticholic acid (OCA), Intercept Pharmaceuticals

Drug: Obeticholic acid (OCA)
Company: Intercept Pharmaceuticals
Phase: Phase III
Class: Farnesoid X receptor (FXR) agonist
2020 sales: $2.99 billion
Net present sales: $11.4 billion

Shares of Intercept Pharmaceuticals ($ICPT) went into overdrive at the beginning of the year, soaring more than 250% on the surprise news that a Phase IIb clinical study for its lead drug funded largely by the NIH ended early after achieving the primary endpoint. Then after momentarily rattling investors with a report on some serious side effects, the biotech bounced back with upbeat data from its Phase III for primary biliary cirrhosis, setting the stage for a regulatory filing. The bile acid analog--which mimics human bile acid and is an agonist for the farnesoid X receptor--is in development for PBC, nonalcoholic steatohepatitis and other liver and intestinal diseases.

For more:
Intercept grabs the spotlight at EASL, builds case for lead drug OCA
Intercept scores a PhIII win for lead drug following Friday night frights
Intercept shares dazzle after early success of PhIIb liver disease drug trial

Obeticholic acid (OCA), Intercept Pharmaceuticals
Read more on

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.